Document:

EX-10.1

 Exhibit 10.1 
  

			
	 BARCLAYS

745 Seventh Avenue
 New
York, New York 10019
	  	 ROYAL BANK OF CANADA

Three World Financial Center

200 Vesey Street
 New
York, New York 10281

 Confidential 

November 4, 2013 
 Ocelot Merger Sub, Inc.

 Open Text Corporation 
 275 Frank Tompa Drive 

Waterloo, Ontario 
 N2L 0A1 

Canada 
 Attention: Paul McFeeters 

Commitment Letter 
 Ladies and
Gentlemen: 
 You have advised Barclays Bank PLC (“Barclays”), Royal Bank of Canada (“Royal Bank”) and RBC
Capital Markets1 (“RBCCM”) (Barclays, Royal Bank and RBCCM collectively,
the “Commitment Parties,” “us” or “we”) that (a) Open Text Corporation (the “Company”) and its subsidiary, Ocelot Merger Sub, Inc. (the “Borrower” and,
together with the Company, “you”), intend to enter into an Agreement and Plan of Merger dated as of November 4, 2013 including the schedules and exhibits thereto (as amended in accordance with the terms of this Commitment
Letter and in effect from time to time, the “Acquisition Agreement”) to effect an acquisition of all of the outstanding equity interests of the entities identified to us as “Gyro” (collectively, the
“Target”) through a merger of the Target into the Borrower (the “Acquisition”) and (b) in connection with the consummation of Acquisition (the date thereof being, the “Closing Date”), the
Borrower intends to incur a first lien term loan facility in an aggregate principal amount of $800.0 million (the “Term Facility”). You have further advised us that the proceeds of the Term Facility, together with cash on hand of
the Company and stock consideration in the form of duly issued common shares of the Company shall be used to (a) finance the Acquisition (including repayment of certain existing debt of the Target and its subsidiaries) and (b) pay the
fees, costs and expenses associated therewith (clause (a) and (b), together with the other transactions contemplated hereby to be entered into and consummated in connection with the Acquisition are herein referred to as the
“Transactions”). Capitalized Terms used but not defined herein are used with the meanings assigned to them on the Exhibits attached hereto (such Exhibits, together with this letter, collectively, the “Commitment
Letter”). 
 Accordingly, based upon the foregoing and subject to the terms set forth below and solely to the conditions set forth
in paragraph 5 below and in the Term Sheet (as defined below) under “Conditions Precedent to Borrowing,” the Commitment Parties are pleased to provide their commitments as follows: 

 

	1 	RBC Capital Markets is a marketing name for the capital markets businesses of Royal Bank of Canada and its affiliates. 

  
 -2- 

 1. Commitment. (a) Barclays (acting alone or through or with affiliates selected by
it) hereby commits (on a several, but not joint basis) to provide to the Borrower, 50% of the Term Facility and (b) Royal Bank (acting alone or through or with affiliates selected by it) hereby commits (on a several, but not joint basis) to
provide to the Borrower, 50% of the Term Facility (Barclays and Royal Bank in such capacities, collectively the “Initial Term Lenders” or the “Lenders”), in each case upon the terms, and subject only to the
conditions set forth in paragraph 5 herein and under “Conditions Precedent to Borrowing,” in the Summary of Principal Terms and Conditions attached hereto as Exhibit A (and incorporated by reference herein) (the “Term
Sheet”) and Additional Conditions Precedent attached hereto as Exhibit B. 
 2. Appointment of Roles. You hereby
appoint Barclays (acting alone or through or with affiliates selected by it) and RBCCM (acting alone or through or with affiliates selected by it) to act as co-lead arrangers and joint bookrunning managers (in such capacities, collectively, the
“Lead Arrangers”) for the Term Facility. It is understood and agreed that no other agents, co-agents, arrangers, co-arrangers, bookrunners, placement agents, initial purchasers, managers or co-managers will be appointed, no other
titles (except as provided herein) will be awarded and no compensation (other than compensation expressly contemplated by the Term Sheet or the Fee Letter referred to below) will be paid in connection with the Term Facility unless you and we shall
so agree. It is further agreed that Barclays shall have “lead left” placement on any Marketing Materials (as defined below) and all other offering or marketing materials in respect of the Term Facility and will perform the duties and
exercise the authority customarily performed and exercised in such role. 
 3. Syndication. The Lead Arrangers intend to commence
syndication of the Term Facility promptly following the date hereof to prospective lenders in consultation with you and until the earlier to occur of (a) a Successful Syndication (as defined in the Fee Letter among us and you dated the date
hereof (the “Fee Letter”)) and (b) 60 days following the funding of the Term Facility (such earlier date, the “Syndication Date”), you agree to use commercially reasonable efforts to assist the Lead Arrangers
in forming a syndicate for the Term Facility reasonably acceptable to us and you; provided that, except as expressly set forth in Section 2 above, such syndication shall not relieve any Commitment Party of its obligations set forth
herein (including its obligations to fund the Term Facility on the Closing Date on the terms and conditions set forth in the Commitment Letter) and, unless you agree in writing, the Commitment Parties shall retain exclusive control over all rights
and obligations with respect to its commitments, including all rights with respect to consents, modifications, waivers and amendments, until after the initial funding of the Term Facility on the Closing Date has occurred. Such syndication will be
accomplished by a variety of means, including direct contact during the syndication for the Term Facility between senior management and advisors of the Borrower, the Company and the prospective lenders, which shall be reasonably acceptable to you.
To assist the Lead Arrangers in their syndication efforts, you hereby agree to use your commercially reasonable efforts (a) to provide and cause your advisors to provide the Lead Arrangers and the syndicate members upon request with all
customary information reasonably deemed necessary by the Lead Arrangers to complete syndication, including but not limited to information and evaluations prepared by you, your advisors or on your behalf relating to the Transactions, (b) to
assist the Lead Arrangers upon request in the preparation of customary marketing materials (the “Marketing Materials”) to be used in connection with the syndication of the Term Facility; provided you shall use commercially
reasonable efforts to ensure that the Marketing Materials for the Term Facility are provided to the Lead Arrangers at least fifteen consecutive business days prior to the Closing Date; provided, further that (i) November 27,
2013 and November 29, 2013 shall not be considered business days for the purposes of such fifteen business day period and (ii) such fifteen business day period shall either end on or prior to December 20, 2013 or, if such period has
not ended on or prior to December 20, 2013, then such period shall commence no earlier than January 6, 2014; (c) upon reasonable advanced notice to make available your senior officers and representatives, to make telephonic or
in-person presentations regarding the business and prospects of the Company and its subsidiaries and/or the Target and its subsidiaries at one or 

  
 -3- 

 
more meetings of proposed lenders at such reasonable times and in such reasonable places (as the case may be) to be mutually agreed upon; (d) to obtain, prior to the commencement of
syndication, a credit rating for the Term Facility and update the corporate and corporate family ratings, as applicable, for the Company from each of Standard & Poor’s Ratings Services and Moody’s Investors Service, Inc. (in each
case, taking into account the Transactions) and participate in a customary manner in the process of securing such ratings; (e) prior to the Syndication Date, to ensure that there shall be no competing issues, offerings, placements or
arrangements of debt securities or commercial bank or other credit facilities by or on behalf of the Company or any of its subsidiaries, or the Target or any of its subsidiaries, being offered, placed or arranged without the consent of the Lead
Arrangers, if such issuance, offering, placement or arrangement would reasonably be expected to materially impair the primary syndication of the Term Facility; and (f) to ensure that the Lead Arrangers’ syndication efforts benefit from the
existing lending and investment banking relationships of the Company, the Target and the Borrower and their respective subsidiaries. Notwithstanding the foregoing in this Section 3 and our right to syndicate our commitment hereunder, it is
agreed that the success of any syndication of and receipt of commitments in respect of all or any portion of our commitments hereunder prior to the funding of the Term Facility shall not be a condition to our commitments hereunder. 

Subject to the terms hereof and limitations and your consent rights set forth herein, the Lead Arrangers will lead the syndication and will
manage, in consultation with you, all aspects of the syndication, including, without limitation, selection of lenders, determination of when the Lead Arrangers will approach potential lenders and the time of acceptance of the lenders’
commitments, any naming rights, the final allocations of the commitments among the lenders and the amount and distribution of fees among the lenders. To assist the Lead Arrangers in their syndication efforts, subject to the limitations in the
preceding paragraph, upon the request of the Lead Arrangers, you agree to use commercially reasonable efforts promptly to prepare and provide to the Lead Arrangers the Marketing Materials with respect to you, and your subsidiaries and the
Transactions, including annual projections of the Company (giving pro forma effect to the Transactions) through 2018 with respect to income statements and balance sheets (the “Projections”), that are not otherwise in any Lead
Arrangers’ possession and that the Lead Arrangers reasonably request in connection with the structuring, arrangement and syndication of the Term Facility. 

At the request of the Commitment Parties, you agree to assist in the preparation of a version of the Marketing Materials (a “Public
Version”) consisting exclusively of information with respect to you and your affiliates, the Target and its subsidiaries and the Acquisition that is either publicly available or not material with respect to you and your affiliates, the
Target and its subsidiaries, any of your or their respective securities or the Acquisition for purposes of United States federal and state securities laws and Canadian securities laws (such information, “Non-MNPI”). Such Public
Versions, together with any other information prepared by you or the Target or your or its affiliates or representatives and conspicuously marked “Public” (collectively, the “Public Information”), which at a minimum means
that the word “Public” will appear prominently on the first page of any such information, may be distributed by us to prospective Lenders who have advised us that they wish to receive only Non-MNPI (“Public Side Lenders”).
You acknowledge and agree that, in addition to Public Information and unless you promptly notify us otherwise, (a) drafts and final definitive documentation with respect to the Term Facility, (b) administrative materials prepared by the
Commitment Parties for prospective Lenders (such as a lender meeting invitation, allocations and funding and closing memoranda) and (c) notifications of changes in the terms of the Term Facility may be distributed to Public Side Lenders. It is
understood that in connection with your assistance described above, customary authorization letters will be included in the Marketing Materials that (i) authorize the distribution thereof to prospective Lenders, (ii) represent that the
Public Version of the Marketing Materials only includes non-MNPI and (iii) exculpate you, the Company, the Target and us and your, our and their respective affiliates with respect to any liability related to the misuse (or, in the case of us
and our affiliates, use) of the contents of the Marketing Materials or related materials 

  
 -4- 

 
by the recipients thereof and, in the case of us, any liability with respect to the contents of such Marketing Materials or related materials. 

4. Fees. As consideration for and a condition precedent to our commitments hereunder and our undertakings to arrange, manage,
structure and syndicate the Term Facility, in the event that the funding of the Term Facility occurs, you agree to pay to us the fees, as and when due and payable as set forth in the Term Sheet and in the Fee Letter. 

5. Conditions. Each Commitment Party’s commitments and agreements and the funding of the Term Facility on the Closing Date
hereunder are subject solely to the conditions set forth in this paragraph, in Exhibit A under the heading “Conditions Precedent to Borrowing” and in Exhibit B. Notwithstanding anything in this Commitment Letter, the Fee
Letter, the Term Facility Documentation (as defined in Exhibit A) or any other agreement or undertaking to the contrary, (a) the only representations relating to you and your subsidiaries and the Target and its subsidiaries and your or
their respective businesses the making and accuracy of which shall be a condition to availability of the Term Facility on the Closing Date shall be (i) such of the representations made by or with respect to the Target in the Acquisition
Agreement as are material to the interests of the Lenders, but only to the extent that you or your affiliate have the right to terminate your obligations under the Acquisition Agreement or not consummate the Acquisition, in each case in accordance
with the terms thereof as a result of a breach of such representations in the Acquisition Agreement (the “Acquisition Agreement Representations”) and (ii) the Specified Representations (as defined below) made by the Company in
the Term Facility Documentation, and (b) the terms of the Term Facility Documentation shall be in a form such that they do not impair availability of the Term Facility on the Closing Date if the conditions set forth in this Commitment Letter
are satisfied (it being understood that, to the extent any collateral (including the creation or perfection of any security interest) referred to in the Term Sheet cannot be provided on the Closing Date (other than the grant and perfection of
security interests (x) in assets with respect to which a lien may be perfected by the filing of a financing statement under the Uniform Commercial Code, the Personal Property Security Act or by the filing of short-form security agreements with
the United States Patent and Trademark Office and Canadian IP filings or (y) in capital stock of any U.S. or Canadian entity with respect to which a lien may be perfected by the delivery of a stock certificate) after your use of commercially
reasonable efforts to do so and without undue burden or expense, then the delivery of such collateral shall not constitute a condition precedent to the availability of the Term Facility on the Closing Date but shall be required to be delivered after
the Closing Date, within 60 days, pursuant to arrangements to be mutually agreed). For purposes hereof, “Specified Representations” means the representations and warranties relating to corporate existence and good standing, absence
of conflicts with charter documents, (in each case, as they relate to the entering into and performance of the Loan Documents (as defined in Exhibit A)), power and authority, due authorization, execution, delivery and enforceability of the
Loan Documents (in each case, as they relate to the entering into and performance of the Loan Documents), solvency of the (a) the Borrower and its subsidiaries on a consolidated basis and (b) Company and its subsidiaries on a consolidated
basis, in each case, after giving effect to the Transactions (such representations and warranties to be consistent with the solvency certificates in the forms attached as Exhibit C and Exhibit C-1 hereto), Federal Reserve margin
regulations, Investment Company Act, PATRIOT Act and OFAC (with respect to PATRIOT ACT and OFAC, solely to the extent that it would be unlawful for the Lenders to extend the loans) and the creation, validity, priority and perfection of security
interests in the Collateral (subject to the parenthetical in clause (b) above). This paragraph, and the provisions herein, shall be referred to as the “Certain Funds Provision”. 

6. Information. You hereby represent and warrant that (a) all written information (in the case of information concerning the
Target and its subsidiaries, to your knowledge), other than the Projections, budgets, estimates and other forward looking statements and information of a general economic or industry nature (the “Information”) that has been or will
be made available to the Commitment 

  
 -5- 

 
Parties by or on behalf of you or any of your representatives or affiliates or Target or any of its representatives or affiliates in connection with the Transactions, when taken as a whole, is or
will be, when furnished, correct in all material respects and does not or will not, as the case may be, taken as a whole, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
contained therein not materially misleading in light of the circumstances under which such statements are made after giving effect to all supplements you provide from time to time in accordance with the second to the last sentence of this paragraph
6 and (b) the Projections, budgets, estimates and other forward-looking statements that have been made or will be made available to the Commitment Parties by or on behalf of you and that have been or will be made available to us or any Lender
by you in connection with the Transactions have been or will be, as the case may be, prepared in good faith based upon assumptions believed by the preparer thereof to be reasonable at the time so made available (it being understood that such
Projections are not to be viewed as facts and are subject to significant uncertainties and contingencies, many of which are beyond your control, and that actual results during the period or periods covered by such Projections may differ
significantly from the projected results and that no assurance can be given that the projected results will be realized). You agree to supplement the Information and the Projections from time to time until the later of the Closing Date and the
Syndication Date so that the representation and covenant in the preceding sentence each remains correct, in all material respects as if the Information and Projections were being made available at such time. In arranging the Term Facility, including
the syndications of the Term Facility, we will be entitled to use and rely primarily on the Information and the Projections without responsibility for independent verification thereof. 

7. Expenses. In the event that the funding of the Term Facility occurs, you agree to pay or reimburse the Commitment Parties for all
reasonable and documented costs and expenses incurred by them or its affiliates in connection with the Term Facility relating to the preparation, negotiation, execution and delivery of this Commitment Letter and Fee Letter, the Loan Documents and
any security arrangements in connection therewith, subject to the provisions of the Fee Letter. You further agree to pay all reasonable and documented costs and expenses of the Commitment Parties and its affiliates incurred in connection with
enforcement of any of its rights and remedies hereunder. In addition, you hereby agree to pay when and as due the fees described in the Fee Letter. 

8. Indemnification. You and the Company agree to indemnify and hold harmless each Commitment Party and its affiliates and the
respective officers, directors, employees, agents and controlling persons of the foregoing (each Commitment Party and each such other person being an “Indemnified Person”; and such affiliates, officers, directors, employees, agents
and controlling persons of any such Indemnified Person are referred to herein as its “related parties”), from and against any and all losses, claims, damages, liabilities and expenses, joint or several, to which any such Indemnified
Person may become subject arising out of or in connection with this Commitment Letter, the Fee Letter, the Term Sheet, the Transactions, the Term Facility, the use of proceeds thereof or any claim, litigation, investigation or proceeding (any of the
foregoing, a “Proceeding”) relating to any of the foregoing, regardless of whether any such Indemnified Person is a party thereto or whether a Proceeding is brought by a third party or by you or any of your affiliates, and to
reimburse each such Indemnified Person within 30 days of receipt of reasonably detailed invoice for any reasonable legal or other out-of-pocket expenses incurred in connection with investigating or defending any of the foregoing; it being understood
and agreed that you shall not be required to reimburse legal fees or expenses of more than one U.S. and one Canadian counsel (and, if reasonably necessary, one firm of local counsel in each other relevant jurisdiction) or more than one other advisor
to all Indemnified Persons, taken as a whole (other than such additional counsel as may be appointed in the event of a conflict); provided that the foregoing indemnity and expense reimbursement will not, as to any Indemnified Person, apply to
losses, claims, damages, liabilities or related expenses to the extent (in each case, as determined by a court of competent jurisdiction in a final and non-appealable decision) (A) (x) they have resulted from the willful misconduct, bad
faith or gross negligence of such Indemnified Person or any of its related parties, (y) they have resulted from a 

  
 -6- 

 
material breach of the obligations of such Indemnified Person or any of such Indemnified Person’s affiliates under this Commitment Letter, the Term Sheet, the Fee Letter or the Term Facility
Documentation when neither you nor any of your affiliates have breached the obligations hereunder or thereunder in any material respect or (B) they relate to any dispute solely among any Indemnified Persons to the extent such dispute does not
arise from any act or omission of you or any of your affiliates (other than claims against an Indemnified Person acting in its capacity as an agent or arranger or similar role hereunder or under the Term Facility Documentation). Notwithstanding any
other provision of this Commitment Letter, (i) no Indemnified Person shall be liable for any damages arising from the use by others of information or other materials obtained through electronic, telecommunications or other information
transmission systems, except to the extent such damages have resulted from the willful misconduct, bad faith or gross negligence, as determined by a court of competent jurisdiction in a final and non-appealable decision, of any Indemnified Person or
any of its related parties or you or any of your affiliates and (ii) neither any Indemnified Person nor you or any of your subsidiaries or affiliates shall be liable for any special, indirect, consequential or punitive damages in connection
with this Commitment Letter, the Fee Letter, the Term Sheet, the Transactions, the Term Facility or any Proceeding (including, but not limited to any loss of profits, business or anticipated savings) other than any such damages incurred or paid by
an Indemnified Party to a third party. Neither you nor the Company shall be liable for any settlement of any Proceeding effected without your written consent (which consent shall not be unreasonably withheld or delayed). Neither you nor the Company
shall, without the prior written consent of any Indemnified Person, effect any settlement of any pending or threatened proceedings in respect of which indemnity could have been sought hereunder by such Indemnified Person unless such settlement
(i) includes an unconditional release of such Indemnified Person in form and substance reasonably satisfactory to such Indemnified Person from all liability or claims that are the subject matter of such proceedings and (ii) does not
include any statement as to or any admission of fault, culpability, wrongdoing or a failure to act by or on behalf of any Indemnified Person. 

9. Confidentiality. You agree that you will not disclose, directly or indirectly, the Fee Letter and the contents thereof or this
Commitment Letter and the Term Sheet and the contents thereof to any person without prior written approval of the Lead Arrangers, except that you may disclose (a) the Commitment Letter, the Term Sheet, the Fee Letter and the contents hereof and
thereof (i) to your and the Company’s officers, directors, agents, employees, attorneys, accountants, advisors, controlling persons or equity holders on a confidential and need-to-know basis and (ii) pursuant to any order of any court
or administrative agency, or as required by applicable law, regulation or compulsory legal process or to the extent requested or required by any governmental and/or regulatory authorities (in which case you agree to inform us promptly thereof to the
extent practicable and not prohibited by applicable law), (b) this Commitment Letter, the Term Sheet and the contents hereof and thereof (and, after your acceptance of the terms hereof and of the Fee Letter and return of executed signature
pages hereto and thereto, the Fee Letter and the contents thereof on a redacted basis, with such redaction to be reasonably acceptable to the Lead Arrangers) to the Seller and its officers, directors, employees, attorneys, accountants and advisors,
controlling persons or equity holders and lenders (and their respective advisors), in each case, in connection with the Transactions and on a confidential and need-to-know basis, (c) the existence and contents of the Term Sheet to any rating
agency in connection with the Transactions, (d) to the extent required by applicable law, the existence and contents of this Commitment Letter and the Term Sheet in any public filing or prospectus and (e) the aggregate fees may be
disclosed as part of a general disclosure of fees, costs and expenses in any funds flow, sources and uses or other similar tables. Further, we shall be permitted to use information related to the syndication and arrangement of the Term Facility in
connection with marketing, press releases or other transactional announcements or updates provided to investor or trade publications in consultation with you. You agree that you will permit us to review and approve (such approval not to be
unreasonably withheld) any reference to the Commitment Parties or any of our affiliates in connection with the Term Facility or the Transactions contained in any press release or similar public disclosure prior to public release. 

  
 -7- 

 You acknowledge that each Commitment Party and its affiliates may be providing debt financing,
equity capital or other services (including, without limitation, financial advisory services) to other companies in respect of which you may have conflicting interests regarding the transactions described herein and otherwise (but, until the earlier
of (x) November 11, 2013, if this Commitment Letter is not executed by you and the Company by such date and (y) the termination of this Commitment Letter pursuant to Section 10 below, not in the capacity of lead arranger, agent
or lender for any new financing of a competing bidder for the Acquisition incurred for such purpose). No Commitment Party nor any of its affiliates will use confidential information obtained from you by virtue of the transactions contemplated by
this Commitment Letter or any of its other relationships with you in connection with the performance by them and their affiliates of services for other companies, and no Commitment Party nor any of its affiliates will furnish any such information to
other companies. By the same token, we will not make available to you confidential information that we have obtained or may obtain from any other customer. You also acknowledge that none of the Commitment Parties nor any of its affiliates has any
obligation to use in connection with the transactions contemplated by this Commitment Letter, or to furnish to you, the Seller or your or its subsidiaries, confidential information obtained by such Commitment Party or any of its affiliates from
other companies. You hereby acknowledge and agree that in connection with all aspects of the Transactions, you and each Commitment Party and any of its affiliates through which such Commitment Party may be acting (each a “Transaction
Affiliate”) have an arm’s length business relationship that creates no fiduciary duty on the part of any Commitment Party or any Transaction Affiliate and each expressly disclaims any fiduciary relationship. None of the Commitment
Parties has provided any legal, accounting, financial advisory, regulatory or tax advice with respect to the Transactions and the other transactions contemplated by this Commitment Letter and the Term Sheet and you have consulted with your own
legal, accounting, financial advisory, regulatory and tax advisors to the extent you have deemed it appropriate to do so, and you waive, to the fullest extent permitted by law, any claims you may have against any Commitment Party for breach of
fiduciary duty or alleged breach of fiduciary duty and agree that none of the Commitment Parties will have any liability (whether direct or indirect) to you in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim
on your behalf, including your equity holders, employees or creditors. 
 10. Termination. Our commitments and undertakings
hereunder shall terminate in their entirety automatically without further notice or action by us on the earliest of (a) May 7, 2014, if the Term Facility Documentation is not executed and delivered by the Company, the Borrower and the
Lenders by such date, (b) the date of execution and delivery of the Term Facility Documentation by the Borrower and the Lenders and the initial funding of the Loans thereunder and (c) the date the Acquisition Agreement terminates or
expires or if the Acquisition is abandoned. 
 The reimbursement, indemnification, syndication, information, jurisdiction, governing law,
waiver of jury trial and confidentiality provisions contained herein shall remain in full force and effect regardless of whether the Term Facility Documentation shall be executed and delivered and notwithstanding the termination of this Commitment
Letter or any Lender’s commitments hereunder; provided that your obligations under this Commitment Letter (other than your obligations with respect to (a) assistance to be provided in connection with the syndication of the Term
Facility and (b) confidentiality) shall automatically terminate and be superseded by the provisions of the Term Facility Documentation governing such matters, to the extent covered thereby, upon the execution and delivery thereof, and you shall
automatically be released from all liability hereunder in connection therewith at such time. 
 11. Assignment; etc. This Commitment
Letter and our commitments and undertakings hereunder shall not be assignable by any party hereto (except by you to an affiliate or a subsidiary of the Company that is reasonably acceptable to the Commitment Parties or any other assignment that
occurs as a matter of law pursuant to the merger at the closing of the Acquisition in accordance with the Acquisition Agreement) without the prior written consent of each other party hereto, 

  
 -8- 

 
and any attempted assignment shall be void and of no effect. In no event shall any Commitment Party be released from its obligations under any portion of this Commitment Letter so assigned except
as provided in Section 2 above with respect to the Additional Agents or in Section 3 above. This Commitment Letter is intended to be solely for the benefit of the parties hereto and is not intended to confer any benefits upon, or create
any rights in favor of, any person other than the parties hereto and the Indemnified Persons, except that any Commitment Party may perform the duties and activities described hereunder through any of its affiliates and the provisions of the third
preceding paragraph shall apply with equal force and effect to any of such affiliates so performing any such duties or activities. 
 12.
Governing Law; Waiver of Jury Trial; etc. THIS COMMITMENT LETTER AND THE FEE LETTER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK; AND TOGETHER CONSTITUTE THE ENTIRE AGREEMENT BETWEEN THE PARTIES
RELATING TO THE SUBJECT MATTER HEREOF AND THEREOF AND SUPERSEDE ANY PREVIOUS AGREEMENT, WRITTEN OR ORAL, BETWEEN THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF AND THEREOF. EACH OF THE PARTIES HERETO WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED UPON CONTRACT, TORT OR OTHERWISE) RELATED TO OR ARISING OUT OF THIS COMMITMENT LETTER, THE FEE LETTER EACH ELEMENT OF THE TRANSACTIONS OR THE PERFORMANCE BY US OR ANY OF OUR AFFILIATES OF THE
SERVICES CONTEMPLATED HEREBY. IN ADDITION, WITH RESPECT TO ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS COMMITMENT LETTER, THE FEE LETTER OR THE TRANSACTIONS OR THE PERFORMANCE OF ANY OF THE PARTIES HEREUNDER, EACH OF THE PARTIES
HERETO HEREBY IRREVOCABLY (A) SUBMIT TO THE EXCLUSIVE JURISDICTION OF (I) THE SUPREME COURT OF THE STATE OF NEW YORK, NEW YORK COUNTY AND (II) THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, LOCATED IN THE
BOROUGH OF NEW YORK, AND ANY APPELLATE COURT FROM ANY SUCH COURT; (B) AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE OR FEDERAL COURT; (C) WAIVE THE DEFENSE OF ANY
INCONVENIENT FORUM TO SUCH NEW YORK STATE OR FEDERAL COURT; (D) AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN ANOTHER JURISDICTION BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED
BY LAW; (E) TO THE EXTENT THAT YOU OR YOUR PROPERTIES OR ASSETS HAVE OR HEREAFTER MAY HAVE ACQUIRED OR BE ENTITLED TO IMMUNITY (SOVEREIGN OR OTHERWISE) FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OF NOTICE,
ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OF A JUDGMENT OR FROM EXECUTION OF A JUDGMENT OR OTHERWISE), FOR YOURSELF OR YOUR PROPERTIES OR ASSETS, AGREE NOT TO CLAIM ANY SUCH IMMUNITY AND WAIVE SUCH IMMUNITY; AND (F) CONSENT
TO SERVICE OF PROCESS BY MAILING OR DELIVERING A COPY OF SUCH PROCESS TO YOU AT YOUR ADDRESS SET FORTH ON THE FIRST PAGE OF THIS LETTER AND AGREE THAT SUCH SERVICE SHALL BE EFFECTIVE WHEN SENT OR DELIVERED. 

Notwithstanding the provisions of this Section 12 of this Commitment Letter, interpretation of the provisions of the Acquisition
Agreement (including with respect to satisfaction of the conditions contained therein, whether the Acquisition has been consummated as contemplated by the Acquisition Agreement and any alleged Company Material Adverse Effect (as defined in the
Acquisition Agreement)) and whether the representations made by or with respect to the Company in the Acquisition 

  
 -9- 

 
Agreement are accurate and whether as a result of any inaccuracy thereof you (or your applicable affiliate) have the right to terminate your (or its) obligations under the Acquisition Agreement
(or the right pursuant to the Acquisition Agreement to decline to consummate the Acquisition), shall be governed and construed in accordance with the laws of the State of Delaware without regard to any conflict of laws principles, provisions or
rules (whether of the State of Delaware or any other jurisdiction) that would result in the application of the laws of any jurisdiction other than the State of Delaware and Section 11.9 of the Acquisition Agreement shall govern with respect
thereto. 
 13. Amendments; Counterparts; etc. No amendment or waiver of any provision hereof, the Fee Letter or of the Term Sheet
shall be effective unless in writing and signed by the parties hereto and then only in the specific instance and for the specific purpose for which given. This Commitment Letter, the Term Sheet and the Fee Letter are the only agreements between the
parties hereto with respect to the matters contemplated hereby and thereby and set forth the entire understanding of the parties with respect thereto. This Commitment Letter may be executed in any number of counterparts and by different parties
hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page of this Commitment
Letter by facsimile transmission (or in “pdf” or similar format by electronic mail) shall be effective as delivery of a manually executed counterpart of this Commitment Letter. 

14. PATRIOT Act Notification. We hereby notify you that pursuant to the requirements of the USA PATRIOT Act, Title III of Pub. L.
107-56 (signed into law October 26, 2001) (as the same may be extended and in effect from time to time, the “PATRIOT Act”) and such other money-laundering legislation applicable to the Borrower and each Guarantor, each
Commitment Party is required to obtain, verify and record information that identifies the Borrower, and each Guarantor, which information includes the name, address, tax identification number and other information regarding the Borrower, and each
Guarantor, that will allow such Commitment Party to identify the Borrower in accordance with the PATRIOT Act. This notice is given in accordance with the requirements of the PATRIOT Act and is effective as to each Commitment Party and each Lender.
You hereby acknowledge and agree that each Commitment Party shall be permitted to share any or all such information with the Lenders. 

15. Public Announcements; Notices. We may, subject to your prior written consent (not to be unreasonably withheld, delayed or
conditioned), and subject to paragraph 9 above, at our expense, publicly announce as we may choose the capacities in which we or our affiliates have acted hereunder. Any notice given pursuant hereto shall be mailed or hand delivered in writing, if
to (a) you, at your address set forth on page one hereof; (b) Barclays, at 745 Seventh Avenue, New York, New York 10019 and (c) Royal Bank and RBCCM, at Three World Financial Center, 200 Vesey Street, New York, New York 10281. 

If the foregoing proposal is acceptable to you, please so confirm by signing and returning to us the duplicate copy of this Commitment Letter
and the Fee Letter enclosed herewith. Unless we receive your executed duplicate copies hereof and thereof by 5:00 p.m., New York City time, on November 11, 2013, our commitments and undertakings hereunder will automatically expire at such time
without further action or notice. 
 Each of the parties hereto agrees that the Commitment Letter is a binding and enforceable agreement
with respect to the subject matter contained herein, it being acknowledged and agreed that the commitments provided hereunder are subject solely to the conditions expressly stated in paragraph 5 herein and under “Conditions Precedent to
Borrowing,” in the Summary of Principal Terms and Conditions attached hereto as Exhibit A and Additional Conditions Precedent attached hereto as Exhibit B (subject to 

  
 -10- 

 
the Certain Funds Provision), including the execution and delivery of the Term Facility Documentation (which shall be negotiated in good faith as required by the Documentation Considerations).

 [Signature Pages Follow] 

 We are pleased to have this opportunity and we look forward to working with you on this
transaction. 
  

			
	Very truly yours,
	
	BARCLAYS BANK PLC
		
	By:	 	 /s/ Christina Park

		 	Name: Christina Park
		 	Title: Managing Director

  
 [Signature Page to
Commitment Letter] 

 
			
	ROYAL BANK OF CANADA
		
	By:	 	 /s/ James S. Wolfe

		 	Name: James S. Wolfe
		 	 Title: Managing Director

Head of US Leveraged Finance

  
 [Signature Page to
Commitment Letter] 

 Accepted and agreed to as of 

the date first written above: 
  

			
	OCELOT MERGER SUB, INC.
		
	By:	 	 /s/ Paul McFeeters

		 	Name: Paul McFeeters
		 	Title: Treasurer
	
	OPEN TEXT CORPORATION
		
	By:	 	 /s/ Paul McFeeters

		 	Name: Paul McFeeters
		 	 Title: Chief Financial Officer and

Chief Administrative Officer

  
 [Signature Page to
Commitment Letter] 

			
	CONFIDENTIAL	 	EXHIBIT A

 $800.0 Million First Lien Term Facility 

Summary of Principal Terms and Conditions 

Capitalized terms used but not defined in this Exhibit A shall have the meanings set forth in the Commitment Letter to which this
Exhibit A is attached. 
  

			
	Borrower:	  	Either Merger Sub initially (and upon the consummation of the Acquisition, the Target) or the Target substantially concurrent with the merger or an affiliate or a subsidiary of the Company that is reasonably acceptable to the Agent
(the “Borrower”).
		
	Lead Arrangers and Joint Bookrunners:	  	Barclays Bank PLC (“Barclays’) and RBC Capital Markets (collectively, the “Lead Arrangers”).
		
	Administrative Agent and Collateral Agent:	  	Barclays will act as the sole administrative agent and sole collateral agent (in such capacities, the “Administrative Agent”) for the Lenders.
		
	Transactions:	  	As described in the Commitment Letter.
		
	Lenders:	  	The Commitment Parties (or one of their affiliates) and a syndicate of financial institutions and other lenders (the “Lenders”) arranged by the Lead Arrangers reasonably acceptable to the Borrower.
		
	Closing Date:	  	The date that the initial loans are made under the Term Facility (the “Closing Date”).
		
	Term Facility:	  	First priority term loan facility in an aggregate principal amount of $800.0 million (the “Term Facility”), which shall be secured on a pari passu basis with the loans made under the Existing Credit Agreement (as
defined below).
		
		  	Loans under the Term Facility (the “Term Loans”) will be available to the Borrower in U.S. dollars.
		
	Incremental Facility:	  	The Term Facility Documentation shall permit the Borrower to add one or more incremental term loan facilities to the Term Facility (each, an “Incremental Facility”) in an amount equal to (i) $250.0 million and
(b) additional amounts subject to pro forma compliance with a senior secured net leverage ratio (to be defined to be net of an amount of unrestricted cash and cash equivalents to be agreed) of no greater than 2.50:1.00; provided that (i)
no Lender will be required to participate in any such Incremental Facility, (ii) no event of default exists or would exist after giving effect thereto (provided that, in the case of an Incremental Facility used to finance a permitted
acquisition, no payment or bankruptcy event of default or default exists or would exist after giving effect thereto), (iii) if the Covenant-Lite Option is not elected, the Borrower is in compliance with the financial covenant, (iv) the
representations

  
 Commitment Letter -
Exhibit A 

  
 -2- 

			
		  	and warranties in the Loan Documents shall be true and correct in all material respects (provided that, solely in the case of an Incremental Facility used to finance a permitted acquisition, the Specified Representations (conformed
as necessary for such acquisition) shall be true and correct in all material respects), (v) the maturity date and weighted average life to maturity of any such Incremental Facility shall be no earlier than the maturity date and weighted average life
to maturity of the Term Facility and (vi) the interest rates and amortization schedule applicable to any Incremental Facility shall be determined by the Borrower and the lenders thereunder; provided that for the first 18 months following the
Closing Date, the all-in yield (whether in the form of interest rate margins, original issue discount, upfront fees or LIBOR/ABR floors) applicable to any Incremental Facility will not be more than 0.50% higher than the corresponding all-in yield
(giving effect to interest rate margins, original issue discount, upfront fees and LIBOR/ABR floors) for the existing Term Facility, unless the interest rate margins with respect to the existing Term Facility is increased by an amount equal to the
difference between the all-in yield with respect to the Incremental Facility and the corresponding all-in yield on the existing Term Facility minus 0.50%; provided that, to the extent such terms and documentation are not consistent with the
Term Facility (except to the extent permitted by clause (v) or (vi) above), they shall be reasonably satisfactory to the Administrative Agent.
		
	Purpose:	  	The proceeds of loans under the Term Facility (together with the proceeds of cash on hand of the Company) will be used to pay the consideration in connection with the Transactions and to pay for fees and expenses related to the
Transactions (the “Transaction Costs”).
		
	Availability:	  	The full amount of the Term Facility must be drawn in a single drawing substantially concurrently with the consummation of the Acquisition. Amounts repaid or prepaid under the Term Facility may not be reborrowed.
		
	Interest Rates and Fees:	  	As set forth in Annex I to the Fee Letter.
		
	Maturity and Amortization:	  	The Term Facility will mature on the date that is seven years after the Closing Date and will be payable in equal quarterly installments in each year in aggregate annual amounts equal to 1.0% of the original principal amount of the
Term Loans, with the balance payable at maturity. The Term Facility Documentation (as defined below) shall provide the right of individual Lenders to agree to extend the maturity of their Term Loans upon the request of the Borrower without the
consent of any other Term Lender.

  
 Commitment Letter -
Exhibit A 

  
 -3- 

			
	Guarantees:	  	Same as provided under the Existing Credit Agreement.
		
	Security:	  	Same as provided under the Existing Credit Agreement. The Term Facility security interests shall be pari passu with those securing the Existing Credit Agreement pursuant to a customary intercreditor agreement with the collateral
agent under the Existing Credit Agreement (the “Intercreditor Agreement”) and shall be first priority, subject to exceptions consistent with the Existing Credit Agreement.
		
	Documentation:	  	The definitive financing documentation for the Term Loan Facility shall contain the terms and conditions set forth in this Commitment Letter, it being understood and agreed that there shall not be any conditions to the funding of
the Term Loan Facility other than as set forth in paragraph 5 of the Commitment Letter, under “Conditions to Borrowing” in this Exhibit A and in Exhibit B. The documentation with respect to the Term Facility (the “Term Facility
Documentation”) shall be consistent with that certain Amended and Restated Credit Agreement initially dated as of October 2, 2006, as amended as of February 15, 2007, as further amended as of September 24, 2009 and as further amended and
restated as of November 9, 2011 by and among Open Text ULC (“OT ULC”), the affiliates of the OT ULC party thereto, Barclays Bank PLC as administrative agent, the other financial institutions party thereto and the lenders party
thereto from time to time (as further amended, amended and restated or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement” and the term loans made thereunder, the “Existing Term
Loans”) with the thresholds and baskets in the representations, warranties, covenants and events of default adjusted, in a manner to be agreed where appropriate, from the Existing Credit Agreement to reflect the Loan Parties’ improved
credit profile and growth (including the increased size after giving effect to the Transactions) since the Existing Credit Agreement was executed and to provide for future growth of the Loan Parties consistent with a financial model prepared by the
Company and reasonably acceptable to the Lead Arrangers; and such other modifications as may be mutually agreed. The other documentation relating to the Term Facility (including, without limitation, any guaranty or collateral documents) (together
with the Term Facility Documentation and the Intercreditor Agreement, the “Loan Documents”) shall be substantially consistent with the corresponding documentation for the Existing Credit Agreement.
		
	Prepayments:	  	Same as applicable to the Existing Term Loans pursuant to the Existing Credit Facility except (i) any prepayment of the Loans in connection with a “repricing transaction” (to be defined in a manner to be mutually agreed)
prior to the six-month anniversary of the Closing Date shall be subject a 1.00% prepayment

  
 Commitment Letter -
Exhibit A 

  
 -4- 

			
		  	premium and (ii) with respect to the other mandatory prepayments set forth in the Existing Credit Facility (other than in connection with a “Change of Control” (as defined in the Existing Credit Facility)), (a) the
satisfaction of the prepayment requirements under the Existing Credit Facility in accordance with its terms shall be a permitted application of such prepayment proceeds under the Term Facility and (b) no such prepayments (other than any prepayment
in respect of the incurrence of non-permitted indebtedness) shall be required if the Borrower is in pro forma compliance with a total net leverage ratio (to be defined to be net of an amount of unrestricted cash and cash equivalents to be agreed) of
no greater than 2.50:1.00.
		
	Conditions Precedent to Borrowing:	  	The conditions set forth in Section 5 of the Commitment Letter and in Exhibit B to the Commitment Letter.
		
	Representations and Warranties; Affirmative and Negative Covenants and Events of Default:	  	Same as the provisions of the Existing Credit Agreement.
		
	Financial Covenant:	  	At the election of the Company (which election shall be made prior to the launch of general syndication of the Term Facility), either (i) the Term Facility shall not be subject to any financial maintenance covenant (the
“Covenant-Lite Option”) or (ii) the Term Facility shall be subject to a total net leverage ratio maintenance covenant set at 4.00:1.00.
		
	Voting:	  	Same as applicable to the Existing Term Loans under the Existing Credit Agreement.
		
	Yield Protection and Increased Costs:	  	Same as the provisions of the Existing Credit Agreement as updated for Dodd-Frank and Basel III provisions customary in the current term loan B market; provided that the applicable Lender is generally making corresponding
demands for similar amounts for similarly situated borrowers pursuant to similar provisions in other loan documents to which such Lender is party.
		
	Assignments and Participations:	  	The Lenders will be permitted to assign loans and commitments on the same terms as applicable to the Existing Term Loans under the Existing Credit Agreement; provided that the Term Facility Documentation shall include
customary debt buyback provisions.
		
	Expenses and Indemnification:	  	The Borrower shall pay on the Closing Date to the extent invoiced in reasonable detail prior thereto, all reasonable and documented out-of-pocket expenses of the Administrative Agent and the Lead Arrangers relating to the
preparation, execution, delivery and administration of the Term Facility Documentation and the other Loan Documents and any other amendment or waiver with respect thereto, subject to the

  
 Commitment Letter -
Exhibit A 

  
 -5- 

			
		  	provisions of the Fee Letter. The indemnification provisions shall be the same as the provisions of the Existing Credit Agreement.
		
	Governing Law and Forum:	  	Ontario, Canada.
		
	Notwithstanding Provision:	  	Notwithstanding any other provision of this Commitment Letter: (i) each subsidiary that is an Excluded Subsidiary (as defined in the Existing Credit Agreement) shall only be subject to representations, warranties, covenants and
events of default under the Term Facility to the same extent as provided in the Existing Credit Agreement; (ii) any default under any covenants (other than payment covenants, negative covenants, financial covenants (if the Covenant Lite Option is
not exercised) and certain customary affirmative covenants) in the Term Facility shall not result in an event of default until the Borrower has received notice thereof from the Administrative Agent and (iii) subsidiaries of the Target (other than
subsidiaries organized in the U.S. and Canada) shall not be required to provide guarantees or security under the Term Facility until 60 days after the Closing Date.
		
	Counsel to Administrative Agent and Lead Arrangers:	  	Davis Polk & Wardwell LLP and Stikeman Elliott LLP.

  
 Commitment Letter -
Exhibit A 

			
	CONFIDENTIAL	 	EXHIBIT B

 Additional Conditions Precedent 

Capitalized terms used in this Exhibit B shall have the meanings set forth in the Commitment Letter to which this Exhibit B is attached and
the other Exhibits to the Commitment Letter. In the case of any such capitalized term that is subject to multiple and differing definitions, the appropriate meaning thereof in this Exhibit B shall be determined by reference to the context in which
it is used. 
 The initial borrowings under the Term Facility shall be subject to the following conditions precedent: 

1. Loan Documents consistent with the Term Sheet and the Commitment Letter shall have been executed and delivered by all parties thereto.
Subject to the Certain Funds Provision, all documents and instruments required to perfect the Administrative Agent’s security interests in the Collateral shall have been executed and delivered and, if applicable, be in the proper form for
filing. 
 2. The Acquisition shall have been consummated, or substantially simultaneously with the initial borrowing under the Term
Facility, shall be consummated, in accordance with the Acquisition Agreement (and no provision of the Acquisition Agreement shall have been waived, amended, supplemented or otherwise modified or any consent thereunder given in a manner material and
adverse to the Lenders without the consent of the Lead Arrangers (such consent not to be unreasonably withheld, delayed or conditioned)) (it being understood that any modification, amendment, consent, waiver or determination in respect of the
definition of “Company Material Adverse Effect” and any reduction in the consideration to be paid in respect of the Acquisition shall in each case be deemed to be material and adverse to the interests of the Lenders). 

3. (a) Except (x) as disclosed in the Worldwide SEC Documents (as defined in the Acquisition Agreement) filed with or furnished to
the SEC (as defined in the Acquisition Agreement) by GXS Worldwide, Inc. on or before November 4, 2013 and publicly available prior to November 4, 2013 (but excluding any risk factor section, any disclosures in any section relating to
forward looking statements and any other disclosures included therein to the extent they are predictive or forward-looking in nature) or (y) as set forth in the Company Disclosure Schedules (as defined in the Acquisition Agreement) (each
section of which qualifies the correspondingly numbered and lettered section of Article 4 of the Acquisition Agreement and any other numbered and lettered Section of Article 4 of the Acquisition Agreement to the extent it is reasonably apparent that
such disclosure is responsive to such other numbered and lettered Section of Article 4 of the Acquisition Agreement) and except for the transactions contemplated by the Acquisition Agreement, since the Company Balance Sheet Date (as defined in the
Acquisition Agreement) until November 4, 2013 there has not been any Company Material Adverse Effect and (b) since November 4, 2013, no Company Material Adverse Effect shall have occurred. For purposes of the foregoing,
“Company Material Adverse Effect” means any circumstance, development, event, occurrence, fact, effect, condition or change (each, an “Effect”) that is, or would reasonably be expected to become, individually or in
the aggregate, materially adverse to (a) the business, results of operations, financial condition, or assets of the Acquired Companies (as defined in the Acquisition Agreement), taken as a whole, or (b) the ability of the Company (as
defined in the Acquisition Agreement) to consummate the transactions contemplated by the Acquisition Agreement on a timely basis; provided, however, that, for the purposes of clause (a) in determining whether a Company Material
Adverse Effect has occurred, no Effect shall be considered to the extent arising out of, relating to or resulting from: (i) changes generally affecting the economy, financial or securities markets; (ii) the announcement of the transactions
contemplated by the Acquisition Agreement (including, but not limited to, any resulting adverse changes in the Company’s (as defined in the Acquisition Agreement) relationship with its employees, customers, partners or suppliers);
(iii) any 

  
 Commitment Letter -
Exhibit B 

 
outbreak or escalation of war (whether or not declared) or any act of terrorism; (iv) general conditions in the industry in which the Acquired Companies operate; (v) any change in Law
(as defined in the Acquisition Agreement); (vi) any change in GAAP (as defined in the Acquisition Agreement); (vii) the Company’s (as defined in the Acquisition Agreement) failure to meet internal or published projections, forecasts
or revenue or earning predictions for any period (but not the underlying causes of such failure unless such underlying causes would otherwise be excepted from this definition); or (viii) any natural disasters or acts of God, provided,
further, that any Effect arising out of or resulting from any change or event referred to in clause (i), (iii), (iv), (v), (vi), or (viii) may constitute, and be taken into account in determining the occurrence of, a Company Material
Adverse Effect to the extent such change or event has a disproportionate impact on the Acquired Companies, taken as a whole, as compared to other companies that operate in the industries in which the Acquired Companies operate. 

4. The Lead Arrangers shall have received (a) GAAP audited consolidated balance sheets and related statements of income, changes in
equity and cash flows of the Company for the three most recent fiscal years and such financial statements of GXS Worldwide, Inc. for the two most recent fiscal years, in each case, ended at least 90 days prior to the Closing Date; and (b) GAAP
unaudited consolidated balance sheets and related statements of income, changes in equity and cash flows of each of the Company and GXS Worldwide, Inc. for each subsequent fiscal quarter after June 30, 2013 and December 31, 2012,
respectively, ended at least 45 days before the Closing Date. 
 5. The Administrative Agent shall have received solvency certificates
substantially in the forms attached hereto as Exhibit C and Exhibit C-1 from the chief financial officer or another senior financial or accounting officer of the Borrower and the Company certifying as to the solvency of (a) the Borrower and its
subsidiaries on a consolidated basis and (b) Company and its subsidiaries on a consolidated basis, in each case, after giving effect to the Transactions and the other transactions contemplated hereby. 

6. The Administrative Agent shall have received such legal opinions (including opinions (i) from counsel to the Borrower and its
subsidiaries (and such counsel may be internal counsel of the Company with respect to general corporate matters) and (ii) from such other special and local counsel as may be reasonably required by the Lead Arrangers), documents and other
instruments as are customary for transactions of this type, including corporate documents and officers’ and public officials’ certifications, customary evidence of authority and customary lien and judgment searches and evidence of
insurance. 
 7. The Borrower and each of the Guarantors shall have provided the documentation and other information to the Lenders that
are reasonably requested by the Lenders no later than ten business days prior to the Closing Date under the applicable “know-your-customer” rules and
regulations, including the PATRIOT Act, in each case at least three business days prior to the Closing Date. 
 8. All accrued fees and
expenses (subject to the provisions of the Fee Letter) and other compensation due and payable to the Administrative Agent, the Lead Arrangers and the Lenders required to be paid on the Closing Date (in each case, to the extent invoiced in reasonable
detail at least two business days prior to the Closing Date) shall have been paid. 

  
 Commitment Letter -
Exhibit B 

 EXHIBIT C 

Form of Company Solvency Certificate 

This Certificate is being delivered pursuant to Section [    ] of the Credit Agreement dated as of [    ] (the
“Credit Agreement”), among [                    ] (the “Borrower”), the Lenders party thereto and Barclays Bank
PLC, as Administrative Agent. Capitalized terms used but not otherwise defined herein shall have the meanings specified in the Credit Agreement. 

The undersigned, [                    ],
hereby certifies that he is the [    ] of Open Text Corporation (the “Parent”) and that he is knowledgeable of the financial and accounting matters of the Parent and its subsidiaries, the Credit Agreement and the
covenants and representations (financial and other) contained therein and that, as such, he is authorized to execute and deliver this Certificate on behalf of the Parent. 

The undersigned, solely in his capacity as an officer of the Parent, and not in his individual capacity, hereby further certifies that on the
date hereof, immediately after the consummation of the Transactions to occur on the date hereof: 
 (a) the aggregate of the
property of Parent and its subsidiaries is, at a fair valuation, sufficient, or, if disposed of at a fairly conducted sale under legal process, would be sufficient, to enable payment of all their obligations, due and accruing due; 

(b) the Parent and its subsidiaries, taken as a whole, are paying their current obligations in the ordinary course of business
as they generally became due; and 
 (c) the Parent and its subsidiaries, taken as a whole, will be able to meet their
obligations as they generally become due. 
 [Signature page follows] 

  
 Commitment Letter -
Exhibit C 

 EXHIBIT C-1 

Form of Borrower Solvency Certificate 

This Certificate is being delivered pursuant to Section [    ] of the Credit Agreement dated as of [    ] (the
“Credit Agreement”), among [                    ] (the “Borrower”), the Lenders party thereto and Barclays Bank
PLC, as Administrative Agent. Capitalized terms used but not otherwise defined herein shall have the meanings specified in the Credit Agreement, the undersigned hereby certifies to the Administrative Agent and Lenders, solely in such
undersigned’s capacity as chief financial officer of the Borrower, and not individually (and without personal liability), and based upon financial information, projections and assumptions (including but not limited to those with respect to
accounting, actuarial, investment and reserving) made in good faith and based on assumptions reasonably believed by the Borrower to be fair in light of facts and circumstances as they exist as of the date hereof (and disclaiming any responsibility
for changes in such facts and circumstances after the date hereof), as follows: 
 As of the date hereof, on a pro forma basis after giving effect to the
consummation of the Transactions, including the making of the Loans under the Credit Agreement on the date hereof, and after giving effect to the application of the proceeds of such Loans: 

 

	 	(a)	the fair value of the assets (on a going concern basis) of the Borrower and its Subsidiaries, on a consolidated basis, exceeds, on a consolidated basis, their debts and liabilities, subordinated, contingent or
otherwise; 

  

	 	(b)	the present fair saleable value of the property (on a going concern basis) of the Borrower and its Subsidiaries, on a consolidated basis, is greater than the amount that will be required to pay the probable liability,
on a consolidated basis, of their debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become absolute and matured in the ordinary course of business; 

 

	 	(c)	the Borrower and its Subsidiaries, on a consolidated basis, are able to pay their debts and liabilities, subordinated, contingent or otherwise, as such liabilities become absolute and matured in the ordinary course of
business; and 

  

	 	(d)	the Borrower and its Subsidiaries, on a consolidated basis, are not engaged in, and are not about to engage in, business contemplated as of the date hereof for which they have unreasonably small capital.

 For purposes of this Solvency Certificate, the amount of any contingent liability at any time shall be computed as the amount that would
reasonably be expected to become an actual and matured liability. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to them in the Credit Agreement. 

The undersigned is familiar with the business and financial position of the Borrower and its Subsidiaries (taken as a whole). In reaching the conclusions set
forth in this Solvency Certificate, the undersigned has made such other investigations and inquiries as the undersigned has deemed appropriate, having taken into account the nature of the particular business anticipated to be conducted by the
Borrower and its Subsidiaries (taken as a whole) after consummation of the Transactions. 
 [Signature page follows] 

  
 Commitment Letter -
Exhibit C-1EX-10.1

 Exhibit 10.1 

TRANSITION AGREEMENT AND RELEASE 

This Transition Agreement and Release (“Agreement”) is made by and between Harrison Dillon (the “Employee”) and Solazyme,
Inc. (“Solazyme”) (collectively referred to as the “Parties” or individually referred to as a “Party”). 

RECITALS 
 WHEREAS, the
Employee is currently the President of Solazyme; 
 WHEREAS, the Employee signed an Employee Proprietary Information and Inventions
Agreement with Solazyme dated October 11, 2004 (the “Confidentiality Agreement”); 
 WHEREAS, Solazyme and the Employee have
entered into Stock Option Agreements, dated various dates (collectively the “Option Agreements”), granting the Employee the option to purchase shares of Solazyme’s common stock, subject to vesting schedules set forth therein and
subject to the terms and conditions of Solazyme’s Second Amended and Restated 2004 Equity Incentive Plan, 2011 Equity Incentive Plan and the applicable Option Agreements; 

WHEREAS, Solazyme and the Employee have entered into Restricted Unit Agreements, dated various dates (collectively the “RSU
Agreements”), granting the Employee rights to shares of Solazyme’s common stock, subject to vesting schedules set forth therein and subject to the terms and conditions of Solazyme’s 2011 Equity Incentive Plan and the applicable RSU
Agreements; 
 WHEREAS, Solazyme and the Employee have agreed on the date hereof that the Employee will separate from employment with
Solazyme; 
 WHEREAS, the separation from employment with Solazyme will be effective September 30, 2013 (the “Separation
Date”); 
 WHEREAS, the Parties agree that the Employee shall provide certain transitional services for Solazyme through and including
the Separation Date (the “Transition Period”) as provided herein, subject to and conditioned upon the Employee remaining compliant with the terms of this Agreement, in exchange for which Solazyme agrees to continue to (i) provide the
Employee his base salary and standard benefits, (ii) allow the Employee to continue to vest in his outstanding stock options and RSUs, in each case for the duration of the Transition Period, and (iii) retain his existing title and
reporting relationships; 
 WHEREAS, subject to the Employee providing the Transition Services (as defined below), and conditioned upon the
Employee entering into this Agreement on or by September 5, 2013 (the “Expiration Date”), Solazyme agrees that on or about the Separation Date, it will provide to the Employee the opportunity to enter into the Separation and Release
Agreement provided as Exhibit A (the “Separation Agreement”), subject to the terms and conditions provided therein; and 

WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the
Employee may have against Solazyme and any of the Releasees (as defined below), including, but not limited to, any and all claims arising out of or in any way related to the Employee’s employment with Solazyme, the transition of that employment
as anticipated herein, or the Employee’s separation from employment with Solazyme; 

  

					
	Page 1	  	CONFIDENTIAL	  	Initial:             

 NOW, THEREFORE, in consideration of the mutual promises made herein, Solazyme and the Employee
hereby agree as follows: 
 COVENANTS 

1. Consideration. 
 a.
Opportunity for Increased Severance Benefits under the Separation Agreement. Subject to the Employee (i) executing this Agreement by the Expiration Date; (ii) executing the Separation Agreement in accordance with the terms set forth
therein; and (iii) complying in full with the terms of this Agreement, the Confidentiality Agreement and the Separation Agreement, Solazyme agrees to provide the Employee the Severance Benefits defined in the Separation Agreement. Subject to
the foregoing conditions, the Employee understands that he shall have the separate choice upon separation from employment with Solazyme as to whether or not to enter into the Separation Agreement, in exchange for the Severance Benefits provided
therein, but that in any regard this Agreement, if executed, shall remain fully binding and enforceable on its own terms. 
 The Employee
acknowledges and agrees that the consideration provided above constitutes benefits to which the Employee was not already entitled and therefore acts as binding and valid consideration for the terms of this Agreement. 

2. Payment of Salary and Receipt of All Benefits. The Employee acknowledges and represents that, as of the date this Agreement is
executed, Solazyme has paid or provided all salary, wages, bonuses, accrued vacation/paid time off, leave, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, stock options,
RSUs, vesting, and any and all other benefits and compensation due and owing to the Employee (other than salary and wages earned since the date of his last paycheck, and other than personal time off accrued but not taken as of the date of this
Agreement). The Employee further acknowledges and represents that he has received any leave to which he was entitled or that he requested, if any, under the California Family Rights Act and/or the Family Medical Leave Act, and that he did not
sustain any workplace injury, during his employment with Solazyme. 
 3. Transition Services. 

a. Services. The Parties agree that during the Transition Period, the Employee shall provide, in good faith, reasonable assistance to
Solazyme in connection with its business activities, intellectual property support and the transitioning of his services and business relationships (the “Transition Services”). 

b. Compensation During Transition Services. The Parties agree, as compensation in full for the Transition Services, that Solazyme shall
continue to pay the Employee his standard base salary and benefits, such as health, disability, accrual of personal time off, and perquisites (to the extent applicable), subject to the applicable terms and conditions of the benefit plans and
Solazyme policies and shall allow the Employee to continue to vest in his outstanding stock options and RSUs, in each case for the duration of the Transition Period. Attached as Exhibit B is a schedule showing the Solazyme options and RSUs
currently held by the Employee, each of which (if presently unvested) will continue to vest should the Employee remain eligible for such vesting pursuant to the terms of this Agreement. 

  
 Page 2 

 c. Early Termination of Transition Services. The Parties agree that Solazyme maintains the
right to terminate the relationship and end the Transition Services (and the Transition Period) at any time prior to the Separation Date in the event that (i) the Employee fails to materially comply with the terms of this Agreement or the
Confidentiality Agreement; or (ii) the Employee engages in any activities that constitute Cause as defined below. Except as provided by a written agreement signed by both the Employee and an authorized executive officer of Solazyme that
expressly allows otherwise, the Transition Services shall not extend beyond the Separation Date. Notwithstanding any early termination or extension to the Separation Date, the Employee agrees to remain bound by the terms of this Agreement, including
but not limited to the release of claims provided herein. 
 d. Cause. For purposes of this Agreement, “Cause” shall mean,
the occurrence of any one or more of the following events: (i) the Employee’s refusal to perform in any material respect his current employment duties; (ii) the Employee’s engagement in conduct that causes demonstrable injury,
monetarily or otherwise, to Solazyme, including, but not limited to, misappropriation or conversion of assets of Solazyme; or (iii) the Employee’s engagement in an act of moral turpitude or conviction of or entry of a plea of nolo
contendere to a felony. 
 4. Employee Release of Claims. The Employee agrees that the foregoing consideration represents settlement
in full of all outstanding obligations owed to the Employee by Solazyme and its current and former officers, directors, employees, agents, investors, attorneys, stockholders, administrators, affiliates, benefit plans, plan administrators, insurers,
trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Except as expressly provided herein, the Employee, on his own behalf and on behalf of his respective heirs,
family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action
relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that the Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and
including the Effective Date of this Agreement, including, without limitation: 
 a. any and all claims relating to or arising from the
Employee’s employment relationship with Solazyme and the transition and anticipated termination of that relationship; 
 b. any and all
claims relating to, or arising from, the Employee’s right to purchase, or actual purchase of shares of stock of Solazyme, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under
applicable state corporate law, and securities fraud under any state or federal law, based on facts and/or actions that have occurred prior to the Effective Date (other than Employee’s ownership right to Solazyme stock or equity awards and any
vesting schedules in regard to such equity awards); 
 c. any and all claims for wrongful discharge of employment; termination in violation
of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of
emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury;
assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; 

  
 Page 3 

 d. any and all claims for violation of any federal, state, or municipal statute, including claims
for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 and 1991 (as amended), and the California Fair Employment and Housing Act (“FEHA”), as amended (including
any claims for age, race, color, ancestry, national origin, disability, medical condition, marital status, sexual orientation, gender, gender identity, gender expression, religious creed, pregnancy, sex discrimination and harassment); the Older
Workers Benefits Protection Act; the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”); the Employee Retirement Income and Securities Act (“ERISA”); the Family and Medical Leave Act (“FMLA”);
the California Family Rights Act (“CFRA”); the federal Americans with Disabilities Act of 1990 (“ADA”); the Lilly Ledbetter Fair Pay Act; the Immigration Reform and Control Act of 1986; the Equal Pay Act, of 1963, as amended;
California Business and Professions Code 17200; Uniform Trade Secrets Act; Sarbanes-Oxley Act; any and all protections pursuant to California’s Labor Code, laws, statutes or orders or the Fair Labor Standards Act (“FLSA”); any wage
and hour law (including any claim for waiting-time penalties); privacy rights; and whistleblower protections; 
 e. any and all claims for
violation of the federal or any state constitution; 
 f. any and all claims arising out of any other laws and regulations relating to
employment or employment discrimination; 
 g. any claim for any loss, cost, damage, or expense arising out of any dispute over the
non-withholding or other tax treatment of any of the proceeds received by the Employee as a result of this Agreement; and 
 h. any and all
claims for attorneys’ fees and costs. 
 The Employee agrees that the release set forth in this section shall be and remain in effect in all respects
as a complete general release as to the matters released. This release does not extend to the payments, benefits or obligations incurred under this Agreement. Except as provided in section 4.b. above, this release does not extend to Employee’s
rights as an equity holder of Solazyme. This release does not extend to the Employee’s contractual or common law rights to an indemnity and/or defense to the extent he is entitled to one by virtue of his employment with the Company and does not
relate to claims released hereunder or under the Separation Agreement. For avoidance of doubt, the Employee is not releasing his rights to an indemnity and defense as they are set forth in the Indemnity Agreement that he and Solazyme executed on or
about April 29, 2011 (the “Indemnity Agreement”). This release does not release claims that cannot be released as a matter of law, including, but not limited to, the Employee’s right to file a charge with or participate in a
charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against Solazyme (with the understanding
that any such filing or participation does not give the Employee the right to recover any monetary damages against Solazyme; the Employee’s release of claims herein bars the Employee from recovering such monetary relief from Solazyme). The
Employee represents that he has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this Section. 

  
 Page 4 

 5. Exclusion of ADEA/OWBPA. The Employee understands and acknowledges that he is not
waiving or releasing by this Agreement any rights he may have under the Age Discrimination in Employment Act of 1967 (“ADEA”) or Older Workers Benefit Protection Act (“OWBPA”), and further understands and agrees that this waiver
and release does not apply to any rights or claims that may arise under the ADEA or OWBPA after the Effective Date of this Agreement. Notwithstanding the foregoing, the Employee acknowledges and agrees that he is not aware of any incidents or events
that might give rise to any federal age related claims, does not believe he has any basis otherwise for any federal age related claims, and does not presently intend to assert any federal age related claims. Moreover, the Employee understands and
agrees that the Separation Agreement does include an ADEA waiver, and fully complies with the requirements for such a waiver (including, but not limited to, a 21-day review period and 7-day revocation period). 

6. Solazyme Release of Claims. Subject to the last sentence of this Section 6, Solazyme releases and forever discharges the
Employee, his personal representatives and heirs from and against any and all claims, liabilities, demands, costs, attorney fees, causes of action and damages, including all consequential and incidental damages, whether known or unknown, arising
from the beginning of time to the Effective Date of this Agreement, including without limitation those relating directly or indirectly to the Employee’s employment with, and/or trustee position with, Solazyme and all claims for personal injury,
defamation, breach of contract, and violation of any federal, state constitution or local statute, law or ordinance and the common law. It is understood and agreed that except for the exceptions set forth in this Agreement and the last sentence of
this Section 6, this is a full and final release in complete settlement of all claims and rights of every nature and kind whatsoever that Solazyme has or may have against the Employee. Solazyme agrees that Solazyme will never make any claim or
demand against the Employee as to any matter released under this Agreement. Notwithstanding the foregoing Solazyme does not release the Employee from any claims resulting from any willful misconduct by the Employee. As of the Effective Date of this
Agreement, Solazyme is not aware of any willful misconduct by the Employee. 
 7. California Civil Code Section 1542. The
Parties acknowledge that they have been advised to consult with legal counsel and are familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as
follows: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME
OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
 The Parties, being aware of
the above code section, agree to expressly waive any rights they may have thereunder, as well as under any other statute or common law principles of similar effect. 

8. No Pending or Future Lawsuits. Each Party represents that he or it has no lawsuits, claims, or actions pending in his or its names,
or on behalf of any other person or entity, against the other Party (and in the case of the Employee against the other Releasees) and do not intend to bring any claims on his or its behalf or on behalf of any other person or entity against the other
Party (and in the case of the Employee against the other Releasees). 

  
 Page 5 

 9. Trade Secrets and Confidential Information/Solazyme Property. The Employee reaffirms
and agrees to observe and abide by the terms of the Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of Solazyme’s trade secrets and confidential and proprietary information, and assignment of
inventions. The Employee’s signature below constitutes his certification under penalty of perjury that other than documents relating to his compensation, equity or employment performance, he has, or no later than the Separation Date will have,
returned all documents and other items provided to the Employee by Solazyme, developed or obtained by the Employee in connection with his employment with Solazyme, or otherwise belonging to Solazyme, except as may be required to satisfy his
obligations under a Consulting Agreement (the “Consulting Agreement”) with Solazyme that may be entered into in conjunction with the Separation Agreement. 

10. No Cooperation. The Parties further agree that they will not knowingly encourage, counsel, or assist any attorneys or their clients
in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against the other Party (and in the case of the Employee against the other Releasees) unless under a subpoena or other
court order to do so or as related directly to the ADEA or OWBPA. Each Party agrees both to immediately notify the other Party upon receipt of any such subpoena or court order, and to furnish, within three (3) business days of its receipt, a
copy of such subpoena or other court order. If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees, the Employee
shall state no more than that he cannot provide counsel or assistance. 
 11. Non-Disparagement. Attached as Exhibit C is an
agreed upon press release concerning the Employee’s transition and planned departure from Solazyme that the Parties will release within three (3) days after the Effective Date of this Agreement. The Parties will utilize the contents of
this statement both for purposes of internal and external communications. In addition, the Employee agrees not to disparage Solazyme, its parent and subsidiary entities, their respective officers, directors, employees, stockholders and agents, or
Solazyme’s products, technologies, or business plans, in any manner likely to be harmful to Solazyme or the other listed entities or persons, or their respective business, business reputations or personal reputation. Likewise, Solazyme will not
disparage and agrees to direct its officers (Senior Vice Presidents and above) and directors not to disparage the Employee in any manner likely to be harmful to him or his business reputation or personal reputation. Nothing in this Section will
prevent any Party from responding accurately and fully to any inquiry or request for information in the course of a government investigation or as required by compulsion of law (including as required by a subpoena). 

12. Breach. The Employee acknowledges and agrees that any material breach of this Agreement, the Separation Agreement (to the extent
executed by the Employee), the Consulting Agreement (to the extent executed by the Employee), or of any provision of the Confidentiality Agreement shall entitle Solazyme immediately to cease providing any further consideration provided to the
Employee under this Agreement, the Separation Agreement or the Consulting Agreement, except as provided by law, in addition to seeking any other appropriate relief allowed by law or in equity. 

13. No Admission of Liability. The Employee understands and acknowledges that this Agreement constitutes a compromise and settlement of
any and all actual or potential disputed claims by the Employee. No action taken by Solazyme hereto, either previously or in connection with this Agreement, shall be deemed or construed to be (a) an admission of the truth or falsity of any
actual or potential claims or (b) an acknowledgment or admission by Solazyme of any fault or liability whatsoever to the Employee or to any third party. 

  
 Page 6 

 14. Non-Solicitation. The Employee acknowledges and agrees that information regarding
employees of Solazyme is confidential information, including without limitation, the names of Solazyme employees, contractors or consultants; information regarding the skills and knowledge of employees, contractors or consultants of Solazyme;
information regarding any past, present, or intended compensation, benefits, policies and incentives for employees, contractors or consultants of Solazyme; and information regarding the management and reporting structure of Solazyme. As a reasonable
measure to protect Solazyme from the harm of such disclosure and use of its confidential information, trade secrets and good-will established against it, the Employee acknowledges and confirms that until the later of twelve (12) months after
(i) the Effective Date and (ii) the termination or expiration date of the Consulting Agreement (if executed by the Employee), the Employee will not, directly or indirectly solicit or attempt to solicit any person who is, an employee,
contractor or consultant with Solazyme, or otherwise solicit, encourage, cause or induce any such employee, contractor or consultant to terminate such relationship with Solazyme. 

15. Costs. The Parties shall each bear their own costs, attorneys’ fees, and other fees incurred in connection with the
preparation of this Agreement and the Separation Agreement. 
 16. Tax Consequences. Solazyme makes no representations or warranties
with respect to the tax consequences of the payments and any other consideration provided to the Employee or made on his behalf under the terms of this Agreement, the Separation Agreement or the Consulting Agreement. The Employee agrees and
understands that he is responsible for payment, if any, of local, state, and/or federal taxes on the payments and any other consideration provided by Solazyme hereunder or pursuant to the Separation Agreement or the Consulting Agreement, and any
penalties or assessments thereon. The Employee further agrees to indemnify and hold Solazyme harmless from any claims, demands, deficiencies, penalties, interest, assessments, executions, judgments, or recoveries by any government agency against
Solazyme for any amounts claimed due from him on account of (a) the Employee’s failure to pay or Solazyme’s failure to withhold, or the Employee’s delayed payment of, federal or state taxes, or (b) damages sustained by
Solazyme by reason of any such claims, including attorneys’ fees and costs. 
 17. Authority. Solazyme represents and warrants
that the undersigned has the authority to act on behalf of Solazyme and to bind Solazyme and all who may claim through it to the terms and conditions of this Agreement. The Employee represents and warrants that he has the capacity to act on his own
behalf and on behalf of all who might claim through him to bind them to the terms and conditions of this Agreement. Each Party warrants and represents that there are no liens or claims of lien or assignments in law or equity or otherwise of or
against any of the claims or causes of action released herein. 
 18. No Representations. Each Party represents that he or it has had
an opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement. Neither Party has relied upon any representations or statements made by the other that are not specifically
set forth in this Agreement. 
 19. Severability. In the event that any provision or any portion of any provision hereof or any
surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without that provision or portion of
provision. 

  
 Page 7 

 20. Attorneys’ Fees. In the event that either Party brings an action to enforce or
effect its rights under this Agreement, the prevailing Party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees incurred in connection with
such an action. 
 21. Entire Agreement. This Agreement, together with the Confidentiality Agreement, the Option Agreements, the RSU
Agreements, the Indemnity Agreement and the Separation Agreement, represents the entire agreement and understanding between Solazyme and the Employee concerning the subject matter of this Agreement and the Employee’s employment with Solazyme,
transition of employment, and anticipated separation from employment with Solazyme and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter of
this Agreement and the Employee’s relationship with Solazyme. 
 22. No Oral Modification. This Agreement may only be amended in
a writing signed by the Employee and an executive officer of Solazyme. 
 23. Governing Law. This Agreement shall be governed by the
laws of the State of California, without regard for choice-of-law provisions. The Employee consents to personal and exclusive jurisdiction and venue in the County of San Mateo in the State of California. 

24. Effective Date. This Agreement will become effective on the date it has been signed by both Parties (the “Effective
Date”). 
 25. Counterparts. This Agreement may be executed in counterparts and by PDF or facsimile, and each counterpart, PDF
and facsimile shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned. 

26. Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been
duly given when personally delivered, when sent by electronic mail or facsimile (provided that receipt is confirmed), when delivered via overnight courier (such notice effective as of the first business day following delivery of the notice to the
overnight courier) or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of the Employee, mailed notices shall be addressed to him at the home address that he most recently communicated to
Solazyme in writing. In the case of Solazyme, mailed notices shall be addressed to Solazyme’s corporate headquarters, and all notices shall be directed to the attention of the General Counsel. 

27. Voluntary Execution of Agreement. Each Party understands and agrees that it or he executed this Agreement voluntarily, without any
duress or undue influence on the part or behalf of the other Party or any third party, with the full intent of releasing all of their claims against the other (and in the case the Employee, the other Releasees), except as specified herein. The
Employee acknowledges that: 
  

	 	(a)	He has read this Agreement; 

  

	 	(b)	He has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his own choice or has elected not to retain legal counsel; 

  
 Page 8 

	 	(c)	He understands the terms and consequences of this Agreement and of the releases it contains; and 

  

	 	(d)	He is fully aware of the legal and binding effect of this Agreement. 

 IN WITNESS WHEREOF, the
Parties have executed this Agreement on the respective dates set forth below. 
  

							
		 		 	Harrison Dillon, an individual
			
	Dated: September 5, 2013	 		 	 /s/ Harrison Dillon

		 		 	 Harrison Dillon

		 		 	SOLAZYME, INC.
				
	Dated: September 5, 2013	 		 	By 	 	/s/ Jonathan Wolfson
		 		 		 	Name: Jonathan Wolfson
		 		 		 	Title: CEO

  
 Page 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]